Navigation Links
Scripps Florida scientists develop a process to disrupt hepatitis C virion production
Date:3/21/2008

Using genetic mapping and biochemical analyses, the authors were able to show that their deletion altered a phosphorylation signal controlling the switch from RNA replication to virus particle assembly. This signal was attributed to the activity of a cellular kinase that when inhibited by genetic or chemical means led to a reduction in infectious virus production without altering HCV RNA replication.

These data provide the first evidence for a function of domain III of NS5A and implicate NS5A as an important regulator of the RNA replication and virion assembly of HCV, Tellinghuisen says. The ability to uncouple virus production from RNA replication may be useful in understanding HCV assembly and may become therapeutically important.

Charles M. Rice, head of the Center for the Study of Hepatitis C at Rockefeller University, comments, This is a spectacular advance linking a specific phosphorylation event by a cellular kinase to hepatitis C virus assembly. Remarkably, the target is a viral nonstructural protein, NS5A, and the data point to a pivotal role for this protein in regulating RNA amplification and infectious virus production. These new data make this multifunctional protein an even more attractive target for developing new anti-virals for treating hepatitis C.


'/>"/>

Contact: Keith McKeown
kmckeown@scrpps.edu
858-784-8134
Scripps Research Institute
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Scripps Research scientists shed new light on how antibodies fight HIV
2. Scripps Health Treats More Than 160 Fire Victims at Emergency Departments Across San Diego County
3. Scripps research scientists discover chemical triggers for aggression in mice
4. Scripps research scientists find new genetic mutation that halts the development of lupus
5. Scripps scientists find calcium channel blockers help normalize lysosomal storage disease cells
6. Scripps scientists peg wind as the force behind fish booms and busts
7. Scripps research scientists devise approach that stops HIV at earliest stage of infection
8. Scripps Florida awarded $7.6 million grant to develop novel treatment for Parkinsons disease
9. Scripps research team wins $4M grant to study effects of chronic marijuana use
10. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
11. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)... -- Klafter & Olsen LLP has filed a,class action l..." or the,"Company") (Nasdaq: ARTC ) and certain o...Western District of Texas on behalf of all persons...Care from January 24, 2008,through July 18, 2008 (...,persons or entities who purchased call options or...
(Date:7/25/2008)...etroviral therapy may be due to genetic factors ,...new study challenges the long-held belief that the...,s ability to restore itself after HIV patients ar...y (HAART). , From 50 percent to 90 percent of H... Intravenous drug use is the main cause of both ty...
(Date:7/25/2008)...BeaconEquity.com announces the,availability of Tra... can view all of the daily trading notes for free ... Trade Alerts include: DUSA Pharmaceuticals Inc. (...(Nasdaq: MBRK ), NovaMed Inc. (Nasdaq:,NOVA), Ado...q: AFFX ) and,Abaxis Inc. (Nasdaq: ABAX )., Joi...
(Date:7/25/2008)...ificant Improvements in Members, Health, ATLANTA,... in health,care quality management solutions for h...entered into a long-term agreement with Wellmark, ...on on Quality(SM) Incent and,Reward Best Practices...primary care clinicians to promote improved qualit...
Breaking Medicine News(10 mins):Health News:Klafter & Olsen LLP Announces That It Has Filed a Class Action Lawsuit Against ArthroCare Corporation on Behalf of Common Stock Holders and Certain Traders in ArthroCare Options 2Health News:Klafter & Olsen LLP Announces That It Has Filed a Class Action Lawsuit Against ArthroCare Corporation on Behalf of Common Stock Holders and Certain Traders in ArthroCare Options 3Health News:Study Disproves Belief That Hepatitis C Blunts HIV Drugs 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 3Health News:MDdatacor Extends Contract with Wellmark, Inc. 2Health News:MDdatacor Extends Contract with Wellmark, Inc. 3
...sociated with cancers, fibrosis and other diseases...say // exposure to asbestos may lay the groundwork... arthritis and multiple sclerosis. Researchers exa... known to be polluted by asbestos. They found thes...
... a frightening experience for children as they oft...ew study shows hypnosis could help reduce distress...re. The study included children who were schedule...y. During a VCUG, a tube is inserted into the blad...
...the poorer quality of life they will have, say res...children participated in the study . Researchers m...rt survey completed by a parent and child self-rep...otional, social and academic functioning of the ch...
...ween fast food consumption and weight gain and ins...eases the risk of obesity and type 2 diabetes. Res...rted fast food habits and changes in bodyweight an...ears. The diets of more than 3,000 young adults we...
Other Medicine News:
(Date:7/22/2008)...ility and Efficacy of Treating Patients with ...NCISCO, and YONGIN-SI, South Korea, July 22 /PRNew...tawa, Ontario), and its South,Korean partner Green...from,a Phase I clinical trial of its first-in-clas...t was well-tolerated and resulted in clear,anti-ca...
(Date:7/22/2008)...tress the Importance to Patients of Passing a ... RICHMOND, Va., July 22 /-...ow-on biologics and biopharmaceuticals, today,anno...ill present at a,Congressional briefing on Friday,...or establishing an approval pathway for follow-on,...
(Date:7/22/2008)... by Columbia University Medical Center Based on ...hnology, The Test Differentiates Squamous From N...lassifying Squamous-Cell Carcinoma of the Lung Wit... of 90 Percent,This is the First CLIA Approved Tes...as Biomarkers for Accurate Diagnosis of Lung Cance...
(Date:7/22/2008)...idual,s Genetic Risk Based on Clinical Data, Pr...al Materials, WALTHAM, Mass., July 22 /PRNewswire...ILI ), today announced the launch of an enhanced t...company,s Heart Health Genetic Test.,The test is c...Heart Health,Genetic Test by Quixtar/Amway. The ne...
Breaking Medicine Technology:Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 2Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 3Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 4Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 2Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 2First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 5Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format 2Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format 3Researchers successfully simulate photosynthesis and design a better leaf 1169 1Researchers successfully simulate photosynthesis and design a better leaf 1169 2Researchers successfully simulate photosynthesis and design a better leaf 1169 3Abnormal immune cells may cause unprovoked anaphylaxis 5990 1Abnormal immune cells may cause unprovoked anaphylaxis 5990 2Abnormal immune cells may cause unprovoked anaphylaxis 5990 3Research highlights important indicators of early stage ovarian cancer 5988 1New technology illuminates protein interactions in living cells 1167 1New technology illuminates protein interactions in living cells 1167 2
...ion Therapeutics,announced today that data on two ...prednate) and ST-602 (fenretinide), will be,presen...for,Research in Vision and Ophthalmology (ARVO) in...tions, the company will be hosting a,reception for...ntly being evaluated in two phase,III clinical tri...
...erlying Cause of,Genetic Disorders and Restores Pr...2007 /PRNewswire/ -- New,preclinical data publishe...ure show that PTC124, an investigational new drug,...ious in a,preclinical model of Duchenne muscular d... 13 percent of the cases of DMD are due,to nonsens...
Other Medicine Technology:Sirion Therapeutics Announces Clinical Data to be Presented at the,2007 Association for Research in Vision and Ophthalmology (ARVO),Annual Meeting 2Sirion Therapeutics Announces Clinical Data to be Presented at the,2007 Association for Research in Vision and Ophthalmology (ARVO),Annual Meeting 3Sirion Therapeutics Announces Clinical Data to be Presented at the,2007 Association for Research in Vision and Ophthalmology (ARVO),Annual Meeting 4Targeting Specific Mutations Reveals Promising New Approach to,Treating Genetic Disorders; Preclinical Data Published in Nature 2Targeting Specific Mutations Reveals Promising New Approach to,Treating Genetic Disorders; Preclinical Data Published in Nature 3Targeting Specific Mutations Reveals Promising New Approach to,Treating Genetic Disorders; Preclinical Data Published in Nature 4
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability.
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability.
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability.
For use with Snap-In Snap-Out-II tip inserts. Available in five styles, the Snap-In Snap-Out-II Laparoscopic Instrument Handles offer the broadest range available.
Medicine Products: